MedTrace Logo

Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets

NCT04899921 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2024-03-26

Study results available
· View outcomes & findings →

Summary

The purpose of this research is to test the safety and effectiveness of the investigational combination of Troriluzole, ipilimumab, and nivolumab, and to learn whether this combination works in treating melanoma that has spread to the brain.

Conditions

Interventions

DRUG

Ipilimumab

Intravenous injection

DRUG

Nivolumab

Intravenously (IV) into the vein

DRUG

Troriluzole

Taken orally

DRUG

Placebo

Taken orally

Sponsors & Collaborators

Principal Investigators

  • Ann W Silk, MD, MS · Dana-Farber Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-30
Primary Completion
2023-05-29
Completion
2023-05-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04899921 on ClinicalTrials.gov